First-in-Human trial launches for aggressive blood cancer combo
NCT ID NCT07455851
Summary
This is the first study to test a new drug, REGN17372, in combination with an existing drug, linvoseltamab, in people with advanced multiple myeloma that has come back or stopped responding to other treatments. The main goals are to find a safe dose for the combination and see if it works better than the single drug alone. The study will enroll about 150 participants who have already tried at least three other treatment lines.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.